KNTE - Kinnate Biopharma says cash runway to last through early 2025
2023-04-17 14:59:28 ET
- Kinnate Biopharma ( NASDAQ: KNTE ) said that the ~$231M in cash, cash equivalents, and investments on hand is enough to fund operations through early 2025.
- The company said it is also advancing two additional candidates into the clinic: KIN-7136 for solid tumors and KIN-8741 for non-small cell lung cancer and advanced solid tumors. The first is expected to enter phase 1 in 2H 2023; the latter in 1H 2024.
- Kinnate ( KNTE ) added that it is stepping back from its CDK12 program and is evaluating strategic alternatives for it .
- The company's most advanced candidate is exarafenib in phase 1 for advanced solid tumors and melanoma.
- Seeking Alpha's Quant Rating views Kinnate ( KNTE ) as a hold.
For further details see:
Kinnate Biopharma says cash runway to last through early 2025